These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 27428401

  • 1. Huntington's Disease: The Most Curable Incurable Brain Disorder?
    Wild EJ.
    EBioMedicine; 2016 Jun; 8():3-4. PubMed ID: 27428401
    [No Abstract] [Full Text] [Related]

  • 2. Piecing together the puzzle of Huntington's disease.
    DeWeerdt S.
    Nature; 2018 May; 557(7707):S36-S37. PubMed ID: 29844552
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Assessing and Modulating Kynurenine Pathway Dynamics in Huntington's Disease: Focus on Kynurenine 3-Monooxygenase.
    Sathyasaikumar KV, Breda C, Schwarcz R, Giorgini F.
    Methods Mol Biol; 2018 May; 1780():397-413. PubMed ID: 29856028
    [Abstract] [Full Text] [Related]

  • 7. Huntington's disease: 4 big questions.
    Nowogrodzki A.
    Nature; 2018 May; 557(7707):S48. PubMed ID: 29844555
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. How the gene behind Huntington's disease could be neutralized.
    Drew L.
    Nature; 2018 May; 557(7707):S39-S41. PubMed ID: 29844556
    [No Abstract] [Full Text] [Related]

  • 11. Discovery of the First Druggable GPR52 Antagonist to Treat Huntington's Disease.
    Komatsu H.
    J Med Chem; 2021 Jan 28; 64(2):938-940. PubMed ID: 33443413
    [Abstract] [Full Text] [Related]

  • 12. Magnetic Resonance Imaging in Huntington's Disease.
    Gregory S, Scahill RI, Rees G, Tabrizi S.
    Methods Mol Biol; 2018 Jan 28; 1780():303-328. PubMed ID: 29856026
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biofluid Biomarkers in Huntington's Disease.
    Rodrigues FB, Byrne LM, Wild EJ.
    Methods Mol Biol; 2018 Jan 28; 1780():329-396. PubMed ID: 29856027
    [Abstract] [Full Text] [Related]

  • 15. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
    Reick C, Ellrichmann G, Tsai T, Lee DH, Wiese S, Gold R, Saft C, Linker RA.
    Exp Neurol; 2016 Nov 28; 285(Pt A):12-23. PubMed ID: 27587303
    [Abstract] [Full Text] [Related]

  • 16. Huntington's Disease Protein Huntingtin Associates with its own mRNA.
    Culver BP, DeClercq J, Dolgalev I, Yu MS, Ma B, Heguy A, Tanese N.
    J Huntingtons Dis; 2016 Nov 28; 5(1):39-51. PubMed ID: 26891106
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
    Wang F, Fischhaber PL, Guo C, Tang TS.
    Epigenomics; 2014 Jun 28; 6(3):287-97. PubMed ID: 25111483
    [Abstract] [Full Text] [Related]

  • 20. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
    Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, Régulier E, Bates GP, Paganetti P.
    J Neurochem; 2008 Feb 28; 104(3):846-58. PubMed ID: 17986219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.